Why the study?
Does XV454 improve inhibition of platelet aggregation compared to abciximab in flow models of thrombosis?
Does XV454 improve inhibition of platelet aggregation compared to abciximab in flow models of thrombosis?
XV454 is a potent GPIIb/IIIa antagonist that achieves maximal inhibition of platelet aggregation at lower receptor occupancy than abciximab in in vitro flow models.
Answers are grounded in this paper and cite their sources.
Should not yet change antiplatelet practice; hypothesis-generating for lower-occupancy GPIIb/IIIa antagonists in thrombosis.
Glycoprotein (GP) IIb/IIIa is pivotal in homotypic platelet aggregation and may also be involved in the heterotypic adhesion of leukocytes and tumor cells to platelets. This study was primarily undertaken to compare the antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist, XV454, to that of abciximab in 2 flow models of platelet thrombus formation: (1) direct shear-induced platelet aggregation imposed by a cone-and-plate rheometer and (2) platelet adhesion onto von Willebrand factor (vWF)/collagen I followed by aggregation in a perfusion system. XV454 inhibited platelet aggregation in a concentration-dependent manner in both experimental models. Maximal inhibition of aggregation was achieved by XV454 at approximately 70% receptor occupancy, which is lower than the >/=85% previously reported for abciximab. At similar levels of receptor blockade (approximately 45%), XV454 appeared to be relatively more effective than abciximab in suppressing platelet aggregation. Neither XV454 nor abciximab inhibited platelet adhesion to collagen. Pretreatment of surface-adherent platelets with either XV454 or abciximab inhibited the attachment of monocytic THP-1 cells under flow. In contrast, the rapidly reversible GPIIb/IIIa inhibitor orbofiban failed to suppress these heterotypic interactions. These findings demonstrate that XV454 is a potent GPIIb/IIIa antagonist with a long receptor-bound lifetime like abciximab and may be beneficial for the treatment/prevention of thrombotic complications.
No takes yet. Share an insight, caveat, or question.
Abulencia et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: